Oncology Today—April 14, 2026

This week’s Oncology update highlights regulatory progress, pivotal clinical data, financing support, and partnership activity across multiple solid tumor programs.

In Today’s Newsletter

Dive deeper

Ask Google AI

Ask ChatGPT

Ask Perplexity

Ask Grok

🧠 REYOBIQ gets pediatric glioma orphan status [1] [US • 08 Apr 2026]

https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-granted-us-fda-orphan-drug-designation
Context: REYOBIQ (Plus Therapeutics, rhenium Re186 obisbemeda) is in development for CNS tumors, including recurrent GBM, leptomeningeal metastases, and pediatric brain cancer.
Key point: FDA granted orphan drug designation for REYOBIQ in pediatric malignant gliomas, with Plus saying the scope also covers pediatric ependymoma.
Implication: Introduces competition that may affect pricing and formulary access.

🎯 CRB-701 moves toward registrational studies in HNSCC and cervical cancer [2] [US • 07 Apr 2026]

https://ir.corbuspharma.com/news-events/press-releases/detail/463/corbus-pharmaceuticals-announces-broad-alignment-with-fda-on-registration-path-for-crb-701-in-second-line-hnscc-and-cervical-cancer
Context: CRB-701 (Corbus Pharmaceuticals, Nectin-4 ADC) has Fast Track designation in HNSCC and cervical cancer.
Key point: Corbus reported broad FDA alignment on single randomized registrational studies in second-line HNSCC and cervical cancer, with ORR proposed for potential accelerated approval and OS for potential full approval.
Implication: May influence prescriber choice and payer reviews pending full data.

🫁 Neladalkib NDA filed in ALK-positive NSCLC [3] [US • 07 Apr 2026]

https://investors.nuvalent.com/2026-04-07-Nuvalent-Announces-Submission-of-New-Drug-Application-to-FDA-for-Neladalkib-in-TKI-Pre-treated-Advanced-ALK-positive-NSCLC
Context: Neladalkib (Nuvalent, ALK-selective inhibitor) is being developed for advanced ALK-positive NSCLC after prior ALK TKI treatment.
Key point: Nuvalent submitted an FDA NDA based on data from the registration-directed ALKOVE-1 Phase 1/2 trial in TKI pre-treated patients.
Implication: May influence prescriber choice and payer reviews pending full data.

💰 MAIA says financing should carry Phase 3 ateganosine trial [4] [US • 08 Apr 2026]

https://ir.maiabiotech.com/news-events/press-releases/detail/172/maia-biotechnology-expects-recent-33-million-capital-raise
Context: Ateganosine (MAIA Biotechnology, THIO) is in the THIO-104 pivotal Phase 3 trial in third-line NSCLC.
Key point: MAIA said net proceeds from its recent $33 million offering are expected to fully fund the ongoing pivotal Phase 3 study through completion.
Implication: Signals pipeline investment and modality expansion.

🤝 Boehringer and BioNTech team up in ES-SCLC [5] [Germany • 09 Apr 2026]

https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-biontech-partnership-advance-sclc-therapy
Context: The planned Phase Ib/II study will combine obrixtamig (Boehringer Ingelheim, DLL3/CD3 T-cell engager) with pumitamig (BioNTech and Bristol Myers Squibb, PD-L1/VEGF-A bispecific antibody).
Key point: Boehringer Ingelheim and BioNTech signed a clinical trial collaboration and supply agreement to test the combination in extensive-stage small cell lung cancer.
Implication: Signals pipeline investment and modality expansion.

🇨🇳 DB-1303/BNT323 application accepted in HER2-positive breast cancer [6] [China • 09 Apr 2026]

https://www.dualitybiologics.com/news/606.html
Context: DB-1303/BNT323 (DualityBio and BioNTech, HER2 ADC) was compared with T-DM1 in a Phase III China study in previously treated HER2-positive unresectable or metastatic breast cancer.
Key point: DualityBio said China’s NMPA accepted the application after the pivotal study met its primary endpoint of PFS, with statistically and clinically significant improvement versus T-DM1.
Implication: May influence prescriber choice and payer reviews pending full data.

🧪 CatalYm doses first patient in Phase 2b HCC study [7] [07 Apr 2026]

https://www.catalym.com/catalym-doses-first-patient-in-phase-2b-trial-evaluating-visugromab-in-combination-with-chemoimmunotherapy-as-second-line-treatment-in-unresectable-metastatic-hepatocellular-carcinoma/
Context: GDFATHER-HCC-01 is evaluating visugromab (CatalYm, anti-GDF-15 antibody) with nivolumab and lenvatinib in second-line unresectable or metastatic HCC after anti-PD-(L)1 therapy.
Key point: CatalYm announced first patient dosed in the randomized Phase 2b trial, its third Phase 2b program for visugromab.
Implication: Signals pipeline investment and modality expansion.

📘 Lifyorli posts survival win in ROSELLA and lands guideline momentum [8] [US • 10 Apr 2026]

https://ir.corcept.com/news-releases/news-release-details/corcept-presents-complete-data-pivotal-rosella-trial-sgo-late
Context: Lifyorli (Corcept, relacorilant) plus nab-paclitaxel was studied in the Phase 3 ROSELLA trial in platinum-resistant ovarian cancer.
Key point: Corcept reported final overall survival data showing a 35% reduction in risk of death, simultaneous Lancet publication, and NCCN preferred-regimen inclusion after FDA approval in March 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🧬 GSK advances B7-H4 ADC in gynaecological cancers [9] [09 Apr 2026]

https://www.gsk.com/en-gb/media/press-releases/gsk-presents-positive-data-for-b7-h4-targeted-adc-in-gynaecological-cancers/
Context: Mocertatug rezetecan (GSK, B7-H4 ADC) was evaluated in the Phase I BEHOLD-1 study in platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.
Key point: GSK reported confirmed ORR of 62% in ovarian cancer and 67% in endometrial cancer at the highest doses evaluated, supporting five Phase III starts in 2026.
Implication: May influence prescriber choice and payer reviews pending full data.

🧫 Phanes starts dose expansion for spevatamig in biliary tract cancer [10] [US • 07 Apr 2026]

https://www.phanesthera.com/news/phanes-therapeutics-announces-dose-expansion-in-clinical-study-of-spevatamig-in-combination-with-chemotherapy-for-treatment-of-biliary-tract-cancer/
Context: Spevatamig (Phanes Therapeutics, claudin 18.2/CD47 bispecific antibody) is being studied with chemotherapy in biliary tract cancer.
Key point: Phanes initiated dose expansion after dose-limiting toxicity clearance at two dose levels.
Implication: Signals pipeline investment and modality expansion.

Why it matters

• Regulatory momentum led the week, with orphan designation, FDA alignment, NDA submission, and NMPA acceptance across multiple programs [1][2][3][6].
• ADC activity remained strong across head and neck, cervical, breast, ovarian, and endometrial cancers, led by CRB-701, DB-1303/BNT323, and mocertatug rezetecan [2][6][9].
• Lung cancer updates spanned multiple modalities, including neladalkib in ALK-positive NSCLC, ateganosine in third-line NSCLC, and a new ES-SCLC combination from Boehringer Ingelheim and BioNTech [3][4][5].
• Corcept’s ROSELLA update stood out for near-term practice relevance, linking Phase 3 survival data, FDA approval, Lancet publication, and NCCN preferred-regimen inclusion in the same cycle [8].
• Earlier-stage development also moved forward, with CatalYm and Phanes advancing novel antibody programs in hard-to-treat solid tumors [7][10].

🎯 Catch up on the Top Obesity news from the past two weeks, curated by the LucidQuest team. 

🎬 Watch on YouTube.

📚 View the full Oncology archive on our research hub page